US Surgeon General to Speak at APS Conference on Analgesic Trials

PASADENA, Calif., January 22, 2018 (Newswire.com) - Lotus Clinical Research is pleased to announce that United States Surgeon General, VADM Jerome M. Adams, MD, MPH, will address the American Pain Society’s Third Annual Conference on Analgesic Trials (APS-CAT) and APS’ Scientific Summit on Sunday, March 4, 2018 at the Disneyland Hotel in Anaheim, CA. Dr. Adams will discuss our country’s growing opioid epidemic and the steps health care professionals can take to help curb the crisis.

Registration for APS-CAT is available here: http://apps.americanpainsociety.org/meeting/?ProductId=15227695. You can register for the full APS Summit, which includes two more days of excellent scientific content, or select “Pre-Con Only.” APS-CAT registration is $150, and includes lunch and refreshments. APS-CAT is a full day from approximately 8AM-5PM; the exact time of Dr. Adams’ presentation is currently TBD with more details to come.

Additionally, the following speakers are confirmed to present at APS-CAT:

Robert Dworkin, MD
Director, Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION)

Neil Singla, MD
Chief Scientific Officer, Lotus Clinical Research

Robert Rappaport, MD
Founder, Analgesic Concepts
Former Director, FDA Division of Anesthesia, Analgesia, and Addiction Products

Nathaniel Katz, MD
CEO, Analgesic Solutions

John Farrar, MD, PhD
Associate Professor, University of Pennsylvania
Co-Director, Biostatistics Analysis Center, Biostatistical and Epidemiology Consulting Center, Center for Clinical Epidemiology and Biostatistics

Roy Freeman, MD
Professor of Neurology, Harvard Medical School
Director, Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center

Ralf Baron, MD
Head, Division of Neurological Pain Research and Therapy; Vice Chair, Department of Neurology, Christian-Albrechts-Universitaet

APS-CAT is a full-day conference focused on optimizing the design and conduct of analgesic clinical trials. APS-CAT involves audience members in dialogue with thought leaders in the field to disseminate the latest scientific and regulatory developments and facilitate collaboration. The conference features a panel format, with each presenter speaking for 30 minutes followed by Q & A. Our goal is to maximize the efficiency of analgesic drug development.

Register Now (you can register for the full APS Summit or select “Pre-Con Only”). Registration is $150, and includes lunch and refreshments.

You do not need to sign up for the full APS meeting to attend APS-CAT, but APS offers 2 additional days of scientific content.

Contact:
Hadley Rakowski
Lotus Clinical Research
802-343-5470
[email protected]
www.lotuscr.com

Source: Lotus Clinical Research